Tweet
promising peptide :
RESULTS:
As compared with the wild PACAP, the in vitro stability and PAC1-specific potency of MPAPO with four mutations (M17L, L27K and M, K, respectively, added to the N- and C-terminus) were increased approximately 31- and 2-fold, respectively. MPAPO can significantly promote the proliferation of mouse corneal epithelium cells and the synapse growth of trigeminal ganglion cells. In experimental animals, MPAPO performed a complete corneal epithelial wound closure in 30 hours and significantly inhibited corneal neovascularization, and the effects were obviously stronger than for wild PACAP and recombinant bovine (rb)-bFGF (an anti-corneal wound drug). Furthermore, MPAPO can increase the lacrimal secretion, which may efficiently improve dry eye.
CONCLUSIONS:
MPAPO may represent a promising external therapeutic peptide for corneal wound repairing or dry eye.
As compared with the wild PACAP, the in vitro stability and PAC1-specific potency of MPAPO with four mutations (M17L, L27K and M, K, respectively, added to the N- and C-terminus) were increased approximately 31- and 2-fold, respectively. MPAPO can significantly promote the proliferation of mouse corneal epithelium cells and the synapse growth of trigeminal ganglion cells. In experimental animals, MPAPO performed a complete corneal epithelial wound closure in 30 hours and significantly inhibited corneal neovascularization, and the effects were obviously stronger than for wild PACAP and recombinant bovine (rb)-bFGF (an anti-corneal wound drug). Furthermore, MPAPO can increase the lacrimal secretion, which may efficiently improve dry eye.
CONCLUSIONS:
MPAPO may represent a promising external therapeutic peptide for corneal wound repairing or dry eye.
In summary, our study provides the new recombinant PACAP-derived peptide MPAPO, with higher stability, which exhibits potent effects in promoting corneal wound repair and lacrimal secretion without neovascularization via selective activation of PAC1 receptor. Currently, clinical therapeutics with few side effects for corneal injury are rare, so the recombinant MPAPO has potential to be developed into an external therapeutic against corneal injury or dry eye.
or here: http://iovs.arvojournals.org/article...icleid=2396446
Comment